Items Tagged ‘BRAF’

October 16th, 2017

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

By

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in […]

View full entry

Tags: BRAF, Colon Cancer, erbitux, News, Precision Cancer Medicine, Rectal Cancer, V600E, vemurafenib, zelboraf


July 17th, 2017

Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know

By

The purpose of precision cancer medicine is not to categorize or classify cancers solely by site of origin, but to define the genomic alterations in the cancer’s DNA that are driving that specific cancer.  Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a genetic abnormality […]

View full entry

Tags: Biomarkers, BRAF, Carcinoembryonic Antigen, CEA, cetuximab, Colon Cancer, colorectal cancer, EGFR, epidermal growth factor receptor, Genetic Mutations, kras, Microsatellite Instability High


March 15th, 2017

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm an estimated 45% of patients who received Tafinlar (dabrafenib) + Mekinist (trametinib) combination therapy are alive versus 31% of patients on BRAF monotherapy with […]

View full entry

Tags: BRAF, mek, Mekinist (trametinib), Melanoma, News, Tafinlar (dabrafenib), Zelboraf (vemurafenib


October 7th, 2015

Zelboraf® Appears Active in Hairy Cell Leukemia That Has Progressed After Other Treatment

By

The medication Zelboraf® (vemurafenib) appears active in the treatment of hairy cell leukemia (HCL) that had progressed after previous therapy. These findings were published in New England Journal of Medicine. Hairy cell leukemia is a rare type of leukemia, or cancer of the immune cells. In HCL, the bone marrow makes too many lymphocytes (a […]

View full entry

Tags: BRAF, Hairy Cell Leukemia, HCL, Leukemia, News, vemurafenib, zelboraf


October 2nd, 2014

BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000 people die of melanoma each […]

View full entry

Tags: BRAF, cobimetinib, cobrim, mek, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, vemurafenib, zelboraf